Arcutis Biotherapeutics
IPOMedical dermatology innovation
Public · Westlake Village, United States · Founded 2016 · $310.5M raised
- Headquarters
- Westlake Village
- Employees
- 201–500
- Founded
- 2016
- Business Model
- B2B
- Website
- arcutis.com
- Total Funding
- $310.5M
- Last Round
- $150.0M Growth EquityFeb 2024
- Rounds
- 3
- Type
- Public
About
Arcutis Biotherapeutics (Nasdaq: ARQT) is a commercial-stage medical dermatology company focused on developing innovative topical treatments for immune-mediated skin diseases including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. Founded in 2016 by a leadership team with experience across 50+ FDA-approved products, the company applies recent advances in inflammation and immunology to bring best-in-class molecules against validated dermatologic targets. With six dermatology clinicians on staff, Arcutis prioritizes meaningful innovation to address urgent unmet needs in skin disease management.
Summary
Arcutis Biotherapeutics is a Biotech company based in Westlake Village, United States, founded in 2016. It has raised $310.5M in total across 3 rounds, most recently a $150.0M Growth Equity round in Feb 2024. Investors include SLR Capital Partners, Goldman Sachs and Cowen.
Tech & App Stack
8 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Feb 2024
Sign up to see all 5 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...